An open label SLV308 safety extension to study S308.3.003 in early PD patients.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Pardoprunox (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Solvay Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2010 Trial sponsor, affiliate changed from Solvay Pharmaceuticals to Abbott labs as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual number of patients added to 202 as reported by ClinicalTrials.gov.